Dr Silverstein on the Efficacy of Abemaciclib Plus Hormonal Therapy in Recurrent Low- or High-Grade Serous Ovarian Cancer

“Patients [with low-grade serous ovarian cancer] are really benefiting from this combination. Putting the data into [perspective]…after these patients progress on single-agent hormonal therapy, [their options are limited to] further chemotherapy or MEK inhibitors, which are [both] toxic. We hope these data can support further study [of CDK4/6 inhibition plus hormonal therapy] in [this patient population].”

Jordyn Silverstein, MD, a hematology/oncology fellow at UCLA Health, discusses data from a study evaluating the efficacy of adding the CDK4/6 inhibitor abemaciclib (Verzenio) to hormonal therapy in patients with recurrent, low- or high-grade serous ovarian cancer or endometroid endometrial cancer.